Infection and Immunity in Pediatric Patients

We aim to understand the role of the host immune system in response to infections in children addressing both infectious and immunological sides. This year the group has deeply analyzed the diferent genetic causes of Chronic Granulomatous Disease, has evaluated the appropiate use of new antifingals in the pediàtric population and has collaborate with the Research Group of Microbiology in defining molecular and clinical features of several viral respiratory infections. The group continuosly increases the amount and quality of its scientific output using a multidisciplinary approach that promotes translational research focused on improving patients’ quality of life. Several national and international grants and prizes have recognized this value-based approach. Our research is currently developed in the context of several national (RITIP, RECLIP) and international initiatives (PENTA, EmprEMA, COVIDHGE, JMF).

eCORE

Woman & Child Health & Rare Diseases

Team

Group Leader
Pere Soler Palacín

Principal Investigator (PI)
Maria Espiau Guarner, Antoni Soriano Arandes

Researchers
Jacques G. Rivière, Andrea Martin Nalda, Natalia Mendoza Palomar, Susana Melendo Pérez, Antoinette Frick, Jorgina Vila Soler, Núria Worner Tomasa, Aurora Fernández Polo, Laura Roig Soria, Adriana Margarit Soler, Beatriz Álvarez Vallejo, Victoria Rello, Anna Creus Costa, Marina Garcia Prat, Laura Batlle Massó

PhD Students
Alba Parra Martínez

Nursing and Technical Staff
Sonia Galindo Maycas, Claudia Broto Cortés, Laura López Seguer, Sonia Rodríguez Tello, Víctor Carretero Pifarré, Stephany Zelada Márquez, Miriam González Amores

Publications

72.3

%Q1

372.30

Impact Factor

7.92

Average Impact Factor

Martinón-Torres F, Navarro-Alonso JA, Garcés-Sánchez M and Soriano-Arades A.
The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions.
Arch Bronconeumol. 2023 Sep;59(9):581-588.
DOI: 10.1016/j.arbres.2023.06.006
IF: 6.33

Batlle-Masó L, Rivière JG, Franco-Jarava C, Martín-Nalda A, Garcia-Prat M, Parra-Martínez A, Soler-Palacín P, et al.
Molecular Challenges in the Diagnosis of X-Linked Chronic Granulomatous Disease: CNVs, Intronic Variants, Skewed X-Chromosome Inactivation, and Gonosomal Mosaicism.
J Clin Immunol. 2023 Nov;43(8):1953-1963.
DOI: 10.1007/s10875-023-01556-x
IF: 8.54

Fernández Ledesma B, Mendoza-Palomar N, Melendo Pérez S, Alfonso JL, Fernandez-Polo A, Soler-Palacín P, et al.
Isavuconazole use and TDM in real-world pediatric practice
Antimicrob Agents Chemother. 2023 Dec14;67(12):e0082923
DOI: 10.1128/aac.00829-23
IF: 4.90

Vila J, Lera E, Andrés C, Piñana M, Rello-Saltor V, Soler-Palacín P, et al.
The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): A long-term, clinical, epidemiologic and economic study.
Influenza Other Respir Viruses. 2023 Jan;17(1):e13085
DOI: 10.1111/irv.13085.
IF: 5.61

Soriano-Arades A, Brett A, Buonsenso D, Emilsson L, de la Fuente Garcia I, Gkentzi D, et al.
Policies on children and schools during the SARS-CoV-2 pandemic in Western Europe.
Front Public Health. 2023 Jul 25:11:1175444.
DOI: 10.3389/fpubh.2023.1175444
IF: 6.46

Projects

RBDCOV: RBD Dimer recombinant protein vaccine against SARSCoV2
Principal Investigator: Pere Soler Palacin
Agency: European Commission H2020
Funding: 395,000 €
Period: 2021-Ongoing

RECOMB: Stem-cell based gene therapy for recombination deficient SCID.
Principal Investigator: Pere Soler Palacin
Agency: European Commission H2020
Funding: 57,500 €
Period: 2018-Ongoing

UNDINE: The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalized medicine.
Principal Investigator: Pere Soler Palacin
Agency: European Commission H2020
Funding: 312,525 €
Period: 2022-Ongoing

SARS-CoV-2 and other respiratory viruses in childhood: different approaches to define predictive models for their diagnosis and epidemiological evolution.
Principal Investigator: Antoni Soriano Arandes
Agency: La Marató TV3
Funding: 299,950 €
Period: 2021-Ongoing

Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early stop of antibiotic Treatment in febrile neutropenic oncohaematological paediatric patients (eSTOP-study).
Principal Investigator: Pere Soler Palacin
Agency: ISCIII
Funding: 135,520 €
Period: 2020-Ongoing

Patents

PIDCAP (Early detection of primary immunodeficiencies in Primary Care).
Priority Number: 1908021605053
Priority Date: 29/07/2019
Applicants: VHIR

Play PROA (Training by gamification in pediatric antimicrobial stewardship programs)
Priority Number: 1907251526961
Priority Date: 05/08/2019
Applicants: VHIR